Halfdan Sorbye

14PUBLICATIONS
39CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersNeurology and neuromuscular diseasesMolecular targetsNeurosciences not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|May 20, 2026
Carcinoembryonic Antigen Flare Under Oxaliplatin-Based Chemotherapy Predicts Benefit from Nivolumab in Metastatic Microsatellite-Stable Colorectal Cancer - A Post Hoc Analysis of METIMMOX Trial Data.

|Mar 30, 2026
Efficacy of FOLFIRINOX in digestive neuroendocrine carcinoma.

B P Butt, H Sorbye, M Ladekarl

|Feb 23, 2026
Exploratory biomarkers for oxaliplatin-induced nivolumab responsiveness in metastatic microsatellite-stable colorectal cancer.

Anne Hansen Ree, Paula A Bousquet, Tina Visnovska

|Feb 05, 2026
Molecular-clinical characteristics and treatment outcomes in 163 metastatic colorectal neuroendocrine carcinomas with a comparison to colorectal adenocarcinomas.

Siren Morken, Seppo W Langer, Geir Olav Hjortland

|Aug 14, 2025
Association rule mining of clinical and biomarker data in neuroendocrine tumors: A prospective study on disease progression.

Ulrich Peter Knigge, Magnus Kjellman, Henning Grønbæk

|Aug 09, 2025
Controversies in NEN: An ENETS position statement on the treatment of patients with Grade 3 well-differentiated neuroendocrine tumours of the gastro-enteropancreatic tract.

Mairéad G McNamara, Halfdan Sorbye, Nehara Begum

Pageof 3

Frequent Collaborators

4 joint publications

Morten Ladekarl

3 joint publications

Siren Morken

3 joint publications

Hege Elvebakken

2 joint publications

Sebastian Meltzer